CAS: 681492-22-8; (R)-2-Methyl-6-Nitro-2-((4-(4-(4-(Trifluoromethoxy)Phenoxy)Piperidin-1-yl)Phenoxy)Methyl)-2,3-Dihydroimidazo[2,1-B]Oxazole

该化合物是一种主要用于治疗多抗药性结核病(MDR-TB)的抗结核药物,被归类为硝二氢-免疫二氮氧新诺明衍生物,其功能是抑制对分子细胞壁的合成,即微菌菌菌细胞壁在Mycobiterium结核病中的基本成分.这一机制破坏了细菌细胞墙的完整性,导致细胞死亡.Delamanid通常使用口服,以其相对有利的药用植物基因特征闻名,包括良好的吸收和代谢.该药物经常与其他抗药剂结合使用,以提高功效并降低抗药性发展的风险.常见副作用可能包括头痛,恶心和潜在的心血管影响,需要在治疗期间进行监测.Delamanid的介绍在应对抗药性结核病菌株构成的挑战方面意义重大,有助于旨在控制和消除结核病的全球卫生努力.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    (R)-3-(4-Bromophenoxy)-2-Methylpropane-1,2-Diol置于tris-(Dibenzylideneacetone)Dipalladium(0),2-二叔丁基磷-2-(N,N-二甲氨基)联苯 三正丁胺,Sodium Acetate,Potassium Carbonate,三乙胺,Potassium Hydroxide体系中,用 甲醇,醋酸叔丁酯,乙酸乙酯,Xylene 作为反应溶剂,化学反应 26.83H,反应生成 迪拉马尼
    参考文献: Synthetic Intermediate Of Oxazole Compound And Method For Producing The Same[fr] Intermédiaire Synthétique D'Un Composé Oxazole Et Procédé De Production Associé
    标题: Synthetic Intermediate Of Oxazole Compound And Method For Producing The Same[fr] Intermédiaire Synthétique D'Un Composé Oxazole Et Procédé De Production Associé
    摘要:本发明的目的是提供一种高产率生产噁唑化合物的方法.该目的可以通过由式(11)表示的化合物实现:其中r1是氢原子或较低的烷基基团;r2是在4-位被取代的1-哌啶基团,所述取代基选自(a1A)苯氧基在苯基上取代一个或多个卤素取代的较低烷氧基团,(a1B)苯氧基取代的较低烷基基团在苯基上取代一个或多个卤素取代的较低烷基基团,(a1C)苯基取代的较低烷氧基较低烷基基团在苯基上取代卤素,(a1D)苯基取代的较低烷基基团在苯基上取代一个或多个卤素取代的较低烷氧基团,(a1E)氨基取代的苯基取代一个或多个卤素取代的较低烷氧基团和较低烷基基团,以及(a1F)苯基取代的较低烷氧基团在苯基上取代一个或多个卤素取代的较低烷氧基团;n是1到6之间的整数;x3是有机磺酰氧基团.

    海关参考信息

    专利信息


    专利号:US-11744867-B2
    优先权日:2017-02-14
    标 题 :Modulation of microbial synthesis of 4-ethylphenol and 4-ethylphenyl sulfate in behavior and disease
    发明人:NEEDHAM BRITTANY D; MAZMANIAN SARKIS K; SHARON GIL; FUNABASHI MASANORI; FISCHBACH MICHAEL A; HSIAO ELAINE Y; PATTERSON PAUL H
    权利人:CALIFORNIA INST OF TECHN; UNIV CALIFORNIA
    摘要:Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

    专利号:US-9908876-B2
    优先权日:2009-11-05
    标 题:Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
    发明人:MILLER MARVIN J; MORASKI GARRETT C; MARKLEY LOWELL D; DAVIS GEORGE E
    权利人:UNIV NOTRE DAME DU LAC
    摘要:Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyhdine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo[1,2-a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.

    专利号:US-2023242482-A9
    优先权日:2019-07-26
    标 题:Discovery, total synthesis, and bioactivity of doscadenamides
    发明人:LUESCH HENDRIK; LIANG XIAO; MATTHEW SUSAN; KWAN JASON C; CHEN QI-YIN; PAUL VALERIE J
    权利人:UNIV FLORIDA; SMITHSONIAN INST
    摘要:The invention is directed towards compounds (e.g., Formulae (I)-(IX)), their mechanism of action, processes to prepare the compounds, methods of activating quorum sensing signaling activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formulae (I)-(IX)).

    专利号:WO-2014161516-A1
    优先权日:2013-04-04
    标 题 :Oxa- and thia-diazoles useful in the treatment of tuberculosis
    发明人:HRABALEK ALEXANDR; ROH JAROSLAV; KARABANOVICH GALINA; KLIMESOVA VERA; NEMECEK JAN; PAVEK PETR
    权利人:UNIVERZITA KARLOVA V PRAZE FARMACEUTICKA FAKULTA V HRADCI KRALOVE
    摘要:A substituted diazole of genera l formula (1) wherein X is 0 or S; R is selected from the group consisting of: H, NH2-, C 1 -C 11 n alkyl, cyclohexyl-, benzyl-, phenyl-, pyridyl- or phenyl- substituted, in positions 2, 3, 4 or 5, by one or more electron-acceptor groups comprising -N02, -N(a lkyl)3, -CF 3 , CC 13, -CN, -COOH, -COOAlk, -COOAr, -CHO, -COAlk, -COAr, -F, -CI, -Br, -I, and/or electron-donor groups comprising -NH 2 , -N Halkyl, -N(alkyl)2, -OH, -Oalkyl, -Oaryl, -NHCOCH 3 , -NHCOalkyl; -NHCOaryl; -alkyl, -aryl, wherein when R 1 and R 3 is -N0 2 , then R 2 a R 4 is -H, or when R 1 and R 3 is -H, then R 2 and R 4 is -N0 2 . These compounds can be prepared by easy synthesis and have low toxicity and significant activity against mycobacteria including their multiresistant strains. The invention provides also a pharmaceutical preparation having substituted diazole of formula (I) as the active ingredient, as well as the use of this substituted diazole as antituberculotic.

    专利号:US-8129544-B2
    优先权日:2002-10-15
    标题:1-substituted-4-nitroimidazole compound and method for preparing the same
    发明人:GOTO FUMITAKA; TAKEMURA NORIAKI; OTANI TADAAKI; HASEGAWA TAKESHI; TSUBOUCHI HIDETSUGU; UTSUMI NAOTO; FUJITA SHIGEKAZU; KURODA HIDEAKI; SHITSUTA TAKUYA; SASAKI HIROFUMI
    权利人:GOTO FUMITAKA; TAKEMURA NORIAKI; OTANI TADAAKI; HASEGAWA TAKESHI; TSUBOUCHI HIDETSUGU; UTSUMI NAOTO; FUJITA SHIGEKAZU; KURODA HIDEAKI; SHITSUTA TAKUYA; SASAKI HIROFUMI; OTSUKA PHARMA CO LTD
    摘要:The present invention relates to a 1-substituted-4-nitroimidazole compound represented by the general formula (1) or a salt thereof, n n(wherein R is a hydrogen atom, a lower alkoxy group-substituted lower alkyl group, a phenyl-lower alkoxy group-substituted lower alkyl group, a cyano-substituted lower alkyl group, a phenyl-lower alkyl group which may have lower alkoxy groups as the substituents in the phenyl ring or a group of the formula —CH 2 R A ; X is a halogen atom or a group of the formula —S(O)n-R 1 ) and method for preparing the same. The compound of the formula (1) is a useful compound as an intermediate for synthesis of various pharmaceutical and agricultural chemicals, particularly, as intermediates for antitubercular agents.

    专利号:US-2022096575-A1
    优先权日:2017-02-14
    标 题 :Modulation of microbial synthesis of 4-ethylphenol and 4-ethylphenyl sulfate in behavior and disease
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海迪赛诺医药集团股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.desano.com
    电话: 021-51323300👤
    📞上海迪赛诺医药集团股份有限公司 ⚠️参考联系方式

    销售电话:021-51323300
    邮箱:info@desano.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infect Drug Resist. 2015 Oct 29;8:359-366. eCollection 2015. Review.
    2: Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist. 2015 Oct 30;8:367-378. eCollection 2015. Review.
    3: Bloemberg GV, Keller PM, Stuckia D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc1505196. doi: 10.5588/ijtld.15.0541-2. doi: 10.5588/ijtld.15.0541. doi: 10.1016/j.jchromb.2015.07.058. Epub 2015 Aug 6. doi: 10.1517/14656566.2015.1080240. Epub 2015 Aug 19. doi: 10.1056/NEJMc1415332. doi: 10.1124/dmd.115.064550. Epub 2015 Jun 8. doi: 10.1124/dmd.115.064527. Epub 2015 Jun 8. doi: 10.2147/TCRM.S71076. eCollection 2015. Review.

    合成参考文献


    参考文献:10.1021/jm1010644
    摘要:Cherian J, Choi I, Nayyar A, Manjunatha UH, Mukherjee T, Lee YS, Boshoff HI, Singh R, Ha YH, Goodwin M, Lakshminarayana SB, Niyomrattanakit P, Jiricek J, Ravindran S, Dick T, Keller TH, Dartois V, Barry CE. Structure–Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824). J. Med. Chem. 2011 Jul 26;54(16):5639–59. doi: 10.1021/jm1010644.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知